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Abstract: In Sudanese traditional medicine, decoctions of the stem bark of Anogeissus leiocarpa
are used for the treatment of tuberculosis (TB). However, this plant has not been investigated
before for its antimycobacterial effects. Our screening results show, for the first time, that many
extracts of various parts of A. leiocarpa exhibit growth inhibitory activity against Mycobacterium
smegmatis. Minimum inhibitory concentration (MIC) values ranged between 625 and 5000 µg/mL,
with an ethyl acetate extract of the root showing the lowest MIC value. The good antimycobacterial
effects of the root part could be due to its high concentration of ellagic acid derivatives, ellagitannins,
and flavonoids. Thin layer chromatography (TLC) fractionation resulted in some fractions with
better activity than the starting point crude methanol extract (MIC 2500 µg/mL). Those fractions
with the lowest MIC values contained a high number of antioxidant compounds. Fractions 3 and
4 (MIC 1500 and 1000 µg/mL, respectively) contained high concentrations of di-methyl ellagic acid
([M-H]− 329.0318). Fraction 6 (MIC 2000 µg/mL) contained a lower concentration of di-methyl ellagic
acid and was not as growth inhibitory as fractions 3 and 4. Moreover, in fraction 3, an acetylated
ellagic acid derivative ([M-H]− 343.0477) and di-methyl-ellagic acid xyloside ([M-H]− 461.0739) were
tentatively characterized. Di-methyl ellagic acid xyloside was also present in fraction 4 and could
strongly contribute to the antimycobacterial effect of this fraction. Additionally, protocatechuic acid
([M-H]− at m/z 153.0196) was present in fraction 4. Our antimycobacterial results obtained from this
research justify the use of A. leiocarpa in Sudanese folk medicine against cough related to TB. Roots,
stem bark, and leaves of A. leiocarpa are sources for new potent anti-TB drug lead compounds.
Keywords: Anogeissus leiocarpa; Africa; tuberculosis; ellagitannins; ellagic acid derivatives; flavonoids;
stilbenes; Mycobacterium smegmatis
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1. Introduction
Tuberculosis (TB) is an infectious disease that mostly affects the lungs, but it also affects other
organs such as bones, kidneys, or the brain [1]. Mycobacterium tuberculosis, the main causative bacterium
of TB, is spread through cough, talk, and/or sneeze. However, age, sex, and socio-economic environment
(poverty), as well as immunosuppression (HIV-infection), are considered as major factors affecting
TB prevalence [1,2]. Approximately one third of the world population is estimated to be infected by
TB, with most infections in a latent phase [3,4], and most of the new global TB cases are localized
in Africa [5]. In 2019, the World Health Organization (WHO) [6] declared that 484,000 of the new
global TB cases were resistant to the first-line antibiotic rifampicin, and 78% of them developed
multidrug-resistant tuberculosis (MDR-TB). The new TB cases in 2018 were predominantly found
among males, with a total of 5.4 million new cases, followed by 3.2 million new TB cases among
females and 1.0 million new TB cases among children [5]. Moreover, at present, 1.0 million children die
annually from MDR-TB [3,4]. According to the WHO, the global TB situation needs a focused effort
and emergency action, with an estimated total cost of US $3.3 billion dollars/year to slow down the
spread of the TB and to hinder the incidence of new resistant strains [1].
In some African countries with high poverty levels, a high number of the deaths among the poor
people result from TB [7]. This is due to the scarcity of new and advanced medical inspection equipment,
as well as laboratories lacking diagnostic equipment, high tariffs for TB drugs (US $25/person), and low
income levels (less than US $1 per person/day) [8]. Thus, in many African countries, a high number
of the TB patients use traditional medicine, including plant-based medicines for the treatment of
prolonged cough and other symptoms related to TB.
In Africa, many plant species belonging to the family Combretaceae are used customarily against
cough and respiratory infections, including prolonged cough [9–12]. Anogeissus leiocarpa, the African
birch (in Sudanese: Al-Sahab I. îDË@) is an example of these plants. A. leiocarpa occurs naturally in
Central, East, and West African countries (Figure 1). According to African plant database and plant list
database 2010 [13], there are nine species belonging to the genus Anogeissus, of which eight are native
to tropical Asia. A. leiocarpa is the only African species, and it grows in various geographical zones and
different vegetation types such as bushlands, savannas, and woodlands, and due to its good tolerance to
drought and high soil salinity, it can even grow in drylands and arid and semi-arid grasslands [9,14,15].
A. leiocarpa is a deciduous tree that can reach heights of 15–18 m (Figure 1B). The bark is greyish
and scaly, and the branches are drooping. The inflorescences are globose heads with yellow flowers,
and the fruits are winged [16] (Figure 1C). In Sudanese traditional medicine, the stem bark is made into
a decoction for the treatment of cough [17]. Additionally, there are ethno-pharmacological reports on
the specific use of A. leiocarpa against tuberculosis, including symptoms such as bloody and prolonged
cough [18,19]. Other uses in African traditional medicine of decoctions and macerations of A. leiocarpa
include a broad spectrum of infectious diseases such as bacterial and fungal infections, as well as
symptoms related to these infections, such as diarrhea and skin rashes [18,20,21].
Comparatively little research has been performed to verify the ethno-pharmacologically claimed
antimicrobial effects of A. leiocarpa, and even fewer publications have dealt with the phytochemistry
of this species (Figure 2). However, in accordance with the traditional medicinal uses of A. leiocarpa,
some researchers have demonstrated significant in vitro antibacterial effects of its extracts against
some bacterial strains, such as Staphylococcus aureus, Pseudomonas aeruginosa, Shigella dysenteriae,
Escherichia coli, and Klebsiella pneumoniae (Figure 2) [18,22–25].
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Figure 1. (A) Occurrence of Anogeissus leiocarpus in Africa according to various vegetation mapping 
projects. (TAFP), red dots; Naturalis Herbarium specimen, yellow spots; Africa Nord project, orange 
spots; FLOTRO project, violet dots (Source: African Plant Database); (B) Anogeissus leiocarpa growing 
in semi-arid and woodland savannah zone in Sudan; (C) leaves and flowers; (D) scaly bark. Photos: 
E. Y. A. Salih and H. H. Gibreel 2006. 
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Figure 2. Trend in the number of research papers on Anogeissus leiocarpa from 1998 to 2017. The figure 
illustrates that most of the research papers have dealt with other research aspects than antimicrobial 
or phytochemical research. Thus, there is a need for more research in the mentioned research areas. 
Source: Scopus research data base. 
Figure 1. (A) Occurrence of Anogeissus leiocarpus in Africa according to various vegetation mapping
projects. (TAFP), red dots; Naturalis Herbarium specimen, yellow spots; Africa Nord project, orange
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Phytochemical studies of extracts from A. leiocarpa have mainly reported on polyphenolic and
phenolic compounds (Figure 3). Among these compound groups, we and other researchers have
reported on the occurrence of a number of ellagitannins, ellagic acid and its derivatives, flavellagic
acid, gallic acid and its derivatives, gallotannins, epicatechin-3-O-gallate, and epicatechin [18,26–30]
(Figure 3). In addition, a number of flavonoids have been reported to occur in A. leiocarpa
(Figure 3) [16,18,26,31–34].
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Till today, only one earlier study investigated the antimycobacterial effects of A. leiocarpa
using the Bacillus Calmette-Guérin tuberculosis vaccine containing a live attenuated strain of
Mycobacterium bovis [20]. However, to the best of our knowledge, A. leiocarpa extracts have not
been tested before against Mycobacterium smegmatis. M. smegmatis is known to have a high genetic
homology with M. tuberculosis, as well as being rather resistant against rifampicin, and it is thus
considered to be a representative organism to use in antimycobacterial testing [35,36]. Therefore, in this
current paper, we present our research that aimed to validate the African traditional medicinal use
of water extracts (macerations) and decoctions of A. leiocarpa against tuberculosis and its symptoms,
such as cough, using M. smegmatis as the test bacterium. This paper presents the antimycobacterial
results of a number of extracts and fractions of various polarities from the stem bark, roots, and leaves
of A. leiocarpa. Additionally, high performance liquid chromatography with a diode array detector
(HPLC-DAD) and ultra-high performance liquid chromatography quadrupole time of flight mass
spectrometry (UHPLC/QTOF-MS) were used for the phytochemical profiling of an antimycobacterial
root extract and its preparative reversed phase 18 (RP18)-thin layer chromatography (TLC) fractions.
Preparative RP18-TLC was used to trace the portion of the root extract that could be responsible for its
good antimycobacterial effects.
2. Results
2.1. Extracts and Their Antimycobacterial Effects
Thirty-nine extracts, four thin layer chromatography fractions, and five pure compounds known
to occur in A. leiocarpa were tested for their growth inhibitory effects on M. smegmatis. The results are
presented in Tables 1 and 2.
Table 1. In vitro antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 of extracts and
fractions of various polarities from Anogeissus leiocarpa roots, stem bark, and leaves. Results obtained
with an agar diffusion method. Activity index (AI) was calculated in relation to rifampicin.
Extracts of Anogeissus leiocarpa IZD SEM AI
R. MeSox 21.33 0.33 0.45
R. acetone 15.45 0.33 0.32
R. hex NA
R. EtOAc 28.50 0.29 0.60
R. aqu 18.67 0.17 0.39
R. Dic 16.00 0.00 0.34
R. H2O* 18.67 0.17 0.39
R. Me* 21.33 0.17 0.45
R. HH2O 13.30 0.17 0.28
Rb. acetone 18.33 0.17 0.39
Rb. Me* 17.67 0.17 0.37
Rb. Dic 16.33 0.17 0.34
Rb. H2O* 18.67 0.17 0.39
Rb. hex NA
W. MeSox 20.17 0.33 0.42
W. hex NA
W. H2O* NA
W. CHCl3 13.67 0.17 0.29
W. HH2O 15.00 0.00 0.32
W. aqu 14.00 0.00 0.29
W. EtOAc 25.17 0.17 0.53
W. Me* 20.33 0.33 0.40
B. EtOAc 28.67 0.17 0.60
B. aqu 25.00 0.00 0.53
B. MeSox 14.83 0.17 0.31
B. hex NA
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Table 1. Cont.
Extracts of Anogeissus leiocarpa IZD SEM AI
B. CHCl3 NA
B. H2O* 17.67 0.17 0.37
B. Me* 18.67 0.17 0.39
B. HH2O 20.67 0.17 0.44
L. EtOAc 30.50 0.29 0.64
L. aqu 24.67 0.17 0.52
L. H2O* 26.67 0.17 0.56
L. hex NA
L. Me* 20.00 0.29 0.42
L. acetone 19.94 0.29 0.42
L. Dic NT
L. MeSox 24.17 0.17 0.51
L. HH2O 20.33 0.33 0.43
Rifampicin 47.5 0.29 1.00
Methanol NA
Hexane NA
W, stem wood; B, stem bark; R, root; L, leaves; Rb, root bark; Me*, cold methanol extracts; EtOAc, ethyl acetate extracts;
hex, hexane extracts; Dic, dichloromethane; CHCl3, chloroform extracts; aqu, aqueous extracts; HH2O), hot water
decoctions; MeSox, methanolic Soxhlet extracts; H2O*, cold water extracts; NA, not active; and NT, not tested;
AI, activity index, which was calculated in relation to the antibiotic rifampicin; IZD, diameter of inhibition zones
recorded in mm as the mean of triplicates (n = 3) ± SEM of three experiments; methanol, and hexane were used as
solvent control; most promising results (IZD ≥ 20 mm) are indicated by bold text. Filter paper disks ( 12.7 mm)
were saturated with 200 µL extracts/fractions (50 mg/mL) and rifampicin (10 mg/mL).
Table 2. Minimum inhibitory concentration of the extracts and fractions of A. leiocarpa against
Mycobacterium smegmatis ATCC 14468.
A. leiocarpa Crude Extracts and Fractions Total Activity (in mL/g) MIC (in µg/mL)
W. MeSox 40.2 5000 **
W. Me* 4.2 5000
B. EtOAc 21.6 2500 **
B. aqu 16 5000
B. HH2O 13.6 5000
R. MeSox and its preparativereversed phase
18(RP18)-thin layer chromatography(TLC) fractions
(Fr3-Fr8)
43.2 2500
Fr 3 (Rf 0.095) 1500 (IC 89) **
Fr 4 (Rf 0.159) 1000 (IC 89) **
Fr 6 (Rf 0.276) 2000 (IC 91) **
Fr 8 (Rf 0.457) 3000 (IC 90) **
R. Me* 5.6 5000
R. EtOAc 7.04 625 **
L. MeSox 101.6 5000
L. HH2O 14.8 5000
L. H2O* 28.4 2500
L. EtOAc 38 2500
Pure compounds known to be present in A. leiocarpa
Gallic acid 500 (IC 98) **
Quercetin 250 (IC 94) **
Apigenin 250 (IC 97) **
Corilagin 1000 (IC 94) **
Ellagic acid 500 (IC 98) **
Rifampicin 39.06 µg/mL (3.90 µg/mL, IC 98) **
** Results obtained with a microplate method. Other results not marked with ** were obtained with an agar diffusion
method. W, stem wood; B, stem bark; R, root; L, leaves; Me*, cold methanol extracts; EtOAc, ethyl acetate extracts;
HH2O, hot water extracts or decoctions; MeSox, methanolic Soxhlet extracts; H2O*, cold water extracts, macerations;
total activity in mL/g; IC, inhibitory concentration that indicates the % of growth inhibition compared to the growth
control at that concentration; Fr3, Fr4, Fr6, and Fr8 were obtained from R. MeSox using RP18-TLC.
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An ethyl acetate extract of the roots of A. leiocarpa showed the lowest MIC value (625 µg/mL) of all
extracts in this study and a large inhibition zone diameter (IZD) of 28.50 mm; additionally, the growth
inhibitory effects of this extract were dose-dependent.
Since a Soxhlet methanol extract of the roots also gave good growth inhibitory results
(IZD 21.33 mm), an attempt was made to find the antimycobacterial components or compound
combinations in this extract using RP18-TLC fractionation (Figure 4). Accordingly, the thin-layer
fractions Fr 3 (Rf 0.09), Fr 4 (Rf 0.15), and Fr 6 (Rf 0.27), all enriched with ellagic acid derivatives,
showed better growth inhibition than the crude extract (MIC 2500 µg/mL), with MIC values of 1500,
1000, and 2000 µg/mL, respectively (Table 2). In comparison, we found that pure ellagic acid gave
an MIC value of 500 µg/mL (Table 2). The most polar TLC fraction, Fr 8 (Rf 0.45) showed a weaker
antimycobacterial effect than the crude extract, with an MIC value of 3000 µg/mL (Table 2).Antibiotics 2020, 9, x 9 of 30 
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As shown in Tables 1 and 2, the hydrophilic extracts of the leaves gave good antimycobacterial
effects in general, such that an ethyl acetate extract gave the largest IZD of 30.50 mm and an MIC
of 2500 µg/mL, followed by a cold water extract (IZD 26.67 mm and MIC 2500 µg/mL), an aqueous
fraction (IZD 24.67 mm), a methanolic Soxhlet extract (IZD 24.17 mm), and a hot water decoction
(IZD 20.33 mm).
Moreover, ethyl acetate extracts of the stem bark and stem wood of A. leiocarpa showed large
diameters of inhibition zones against the growth of M. smegmatis (IZD 28.67 and 25.17 mm, respectively,
and an MIC value of 2500 µg/mL for the ethyl acetate fraction of the stem bark).
In contrast to the whole root, only weak or no growth inhibition was observed for the root bark
extracts of A. leiocarpa (Table 1).
In contrast t the more polar extracts, less polar or non-polar extracts such as dichloromethane
and n-hexane extracts of the various parts of A. leiocarpa mostly showed weak or no growth inhibition
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of M. smegmatis (Table 1). This result was in accordance with previous research that non-polar extracts
of A. leiocarpa were not active against a number of strains of gram-positive bacteria [21].
2.2. Phytochemistry and Antioxidant Effects
We made a reversed phase 18 (RP18) TLC fractionation in order to decipher compounds or
combinations of compounds in a methanol Soxhlet root extract of A. leiocarpa that could contribute
to the good antimycobacterial effects of this extract. Our TLC-fractionation resulted in 12 fractions
(Figure 4), of which four (Fr 3, Fr 4, Fr 6, and Fr 8) (Figure 4) were obtained in sufficient concentrations
to be used for antimycobacterial testing and the phytochemical analysis. Our HPLC-DAD and
UHPLC/QTOF-MS results of the qualitative composition of the separated TLC fractions revealed
that the fractions Fr 3, Fr 4, and Fr 6 contained ellagic acid derivatives as their main compounds
(Table 3 and Figure 5B). The HPLC-DAD retention times, [M-H]- data, and (UVλ) absorption spectra of
compounds characterized from the TLC fractions of the root methanol extract of A. leiocarpa are shown
in Table 3. Fraction 3 (Fr 3), the most non-polar part of the crude methanol root extract, appeared as
a fluorescent blue spot on the TLC plate at 366 nm (Figure 4). Fraction 3 contained six compounds
altogether, all ellagic acid derivatives, and three of these compounds—(18) di-methyl ellagic acid
xyloside (C21H18O12, tR 23.47 min, [M-H]− at m/z 461.0766), (21) di-methyl-ellagic acid (C16H10O8,
tR 28.04 min, [M-H]− at m/z 329.0318), and (24) an acetylated ellagic acid derivative (tR 35.08, [M-H]−
at m/z 343.0477)—could be characterized from this fraction (Table 3). Di-methyl ellagic acid was also
found in fractions Fr 4 and Fr 6, and it was the main compound both in Fr 4 and Fr 3 (Table 3 and
Figure 4). Moreover, di-methyl ellagic acid xyloside was also present in Fr 4. Additionally, in fraction
Fr 4, (2) protocatechuic acid (syn. dihydroxybenzoic acid, C7H6O4, tR 3.69 min, [M-H]− at m/z 153.0196)
was present, although it was assumed that this compound would mainly appear in the most polar TLC
fractions (Table 3). In addition, in each TLC fraction, there were a number of ellagic acid derivatives,
for which only the UVλ maxima absorption spectra from HPLC-DAD could be obtained (Table 3).
Five unknown ellagitannins (4b), (19), (20), (22a) and (22b) were present in the crude methanol
extract of the roots of A. leiocarpa at tR (HPLC-DAD) 8.99, 26.10, 27.68, 31.24, and 31.58 min, respectively
(Figure 5A). These ellagitannins were not found in the TLC fractions. However, a small concentration
of an unknown ellagitannin (HPLC-DAD peak area 2.9%) was detected in Fr 6 at tR 23.64 min
(Table 3 and Figure 5B).
As shown in Figure 4I,II and Table 3, we made a qualitative analysis of the antioxidant capacity of
compounds in the TLC fractions of A. leiocarpa roots by spraying TLC plates containing these fractions
with a DPPH reagent. Our results showed that all TLC fractions contained compounds with good
antioxidant effects, but the strongest effects were shown by fractions 3, 4, and 6.
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Table 3. HPLC-DAD, UHPLC/QTOF-MS and RP18 TLC data of fractions obtained from a methanol Soxhlet root extract of A. leiocarpa. Some compounds numbered
according to the HPLC-DAD chromatograms in Figure 5.
RP18-Thin Layer Chromatography
Fractions and Their Compounds
Molecular
Formula Rt HPLC-DAD Rt LC-MS [M-H]
− Exact Calculated
MW
UVλ max
(HPLC-DAD)
Peak Area
%
Distance Moved in
cm on TLC Plate
RP18 TLC
Rf Value
DPPH
Reactive
Fr3 MeSox 1.2 0.0945 Yes
Ellagic acid derivative 20.04 254, 366 2.71
Di-methyl ellagic acid xyloside (18) C21H18O12 23.47 9.65 461.0739 462.0739 246, 376 4.93
Di-methyl-ellagic acid (21) C16H10O8 28.09 11.25 329.0318 330.0318 246, 380 38.43
Ellagic acid derivative 29.94 248, 374 8.05
Unknown 33.06 216, 248, 374 4.31
Acetylated ellagic acid derivative (24) 35.08 12.80 343.0477 344.0477 222, 246, 370 5.99
Fr4 MeSox 1.9 0.1496 Yes
Protocatechuic acid (2) C7H6O4 3.69 1.34 153.0196 154.0196
218, 220, 260,
294 1.5
Ellagic acid derivative 18.12 246, 370 1.63
Ellagic acid derivative 18.90 210, 254, 362 1.7
Ellagic acid derivative 19.98 210, 254, 368 19.12
Di-methyl ellagic acid xyloside (18) C21H18O12 23.52 246, 376 9.09
Di-methyl ellagic acid (21) C16H10O8 28.07 11.25 329.0318 330.0318 246, 380 21.92
Ellagic acid derivative 35.08 246, 382 3.18
Fr6 MeSox 3.5 0.2756 Yes
Unknown flavonoid (9a) 14.66 232, 276, 350 2.31
Ellagic acid derivative 17.54 254, 378 9.84
Ellagic acid derivative 18.12 246, 370 13.41
Unknown 18.93 254, 360 7.77
Ellagic acid derivatives 19.99 254, 362 22.09
ellagitannin (unknown) 23.64 220, 248, 378 2.92
Di-methyl ellagic acid (21) C16H10O8 29.01 11.25 329.0318 330.0318 248, 376 3.99
Fr8 MeSox 5.8 0.4567 Yes
Unknown 5.057 242 3.65
Unknown 13.07 210, 230, 282 3.99
Ellagic acid derivative 17.52 254, 384 3.96
(Fr), fraction; (DMF), distance moved by fraction on the RP18-TLC plate; DPPH, 2,2-diphenoyl-1picrylhydrazyl reagent measuring antioxidant activity; and MW, exact calculated mass that
was calculated from the molecular formula.
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3. Discussion
Our results demonstrated that polyphenol-rich extracts and fractions of the root, leaf. and stem
bark of Anogeissus leiocarpa possess good antimycobacterial effects against M. smegmatis. Surprisingly,
although there have been a number of publications dealing with the antibacterial effects and
phytochemistry of A. leiocarpa, no research has previously been done on the antimycobacterial effects of
A. leiocarpa extracts against M. smegmatis or M. tuberculosis. Thus, our results now prompt more research
on antimycobacterial fractions and compounds in this plant and related species. In the following
parts of the discussion section, we discuss the most potent extracts and fractions, the impact of their
extraction yields and antioxidative effects on their antimycobacterial activities, and the compounds in
these extracts and fractions that are likely to contribute to their antimycobacterial effects.
3.1. Extraction Yields, Total Antimycobacterial Activity and Antioxidative Effects
The % yield of extraction in relation to the MIC gives an important indication for the total
antimicrobial activity of a plant extract. Eloff, 2000 [37] presented the total activity of a plant extract
as the mass extracted from the plant material (in mg/1000 mg starting material) divided by the MIC
value (in mg/mL) of this extract. The total activity is an indication of the volume to which 1 g of a plant
extract can be diluted without losing its antibacterial effect, and it is expressed as mL/g. In respect to
this, the extraction yields resulting from our extractions when using different solvents were taken into
account for A. leiocarpa in order to estimate the total activities of the extracts (Table 2). This information
could be important to improve the use of A. leiocarpa as traditional medicine for the treatment of TB.
In general, our results indicated that the most polar extracts, such as methanol and water extracts,
gave better extraction yields when compared to the non-polar solvents (Figure 6). The extraction
yields of the decoctions and macerations of A. leiocarpa were, however, quite low in general; 11.9% for
a root bark decoction, 7.1% for a maceration of the leaves, and 4.7% for a maceration of the stem bark
(Figure 5). Therefore, the use of water as extractant is maybe not optimal while preparing traditional
remedies of A. leiocarpa. Our results suggested that ethanol extracts could be an option to macerations
and decoctions to extract an optimal concentration of antimycobacterial compounds.
Moreover, in agreement with Orlando et al. [26], we found that the extraction yields considerably
varied between different plant parts, such that Soxhlet extraction with methanol resulted in a low
extraction yield for the roots (10.8%) compared to the stem bark (47.1%) and leaves (50.8%) (Figure 6).
Thus, the total antimycobacterial activity for the root Soxhlet methanol extract was calculated to be
43.2 mL/g (108 mg extracted from 1 g plant material divided by the MIC in mg/mL, 2.5 mg/mL).
For the leaves, the total activity was 101.6 mL/g, even though the MIC value for the leaf Soxhlet
methanol extract was as high as 5000 µg/mL. Thus, despite of the lower MIC value of the root methanol
extract compared to the leaf methanol extract, the total activity of the leaf Soxhlet extract was better
(Table 2). This also implies that leaf extracts in alcohol of A. leiocarpa could be good sources for
antimycobacterial compounds, since the extraction yields with alcohol are high.
Small extraction yields could limit the use of some extracts of A. leiocarpa (and plants in general) as
sources of antimycobacterial compounds. Moreover, the active compounds can sometimes be present
in very small concentrations, which could be a hinderance when trying to elucidate antimycobacterial
compound structures [38].
According to our qualitative DPPH-TLC assay of thin-layer chromatography fractions obtained
from a methanol root extract of A. leiocarpa, some of the fractions, such as Fr 3, Fr 4, and Fr 6,
gave strong antioxidative effects (Figure 4). These antioxidant effects could have positive impacts
on the antimycobacterial effects of the mentioned TLC fractions. Our results are in accordance
with previous research that A. leiocarpa contains a number of polyphenolic compounds with good
antioxidant effects [32].
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Figure 6. Percentage of extraction yield. (A) ethyl acetate (EtOAc), aqueous (aqu), and acetone (acet) in sequential extraction; (B) hot (HH2O) and cold water (H2O*)
extraction; and (C) methanol extraction, Soxhlet extraction (Me sox), and cold methanol extraction (Me*); (A.L.), Anogeissus leiocarpa; (Rb), root bark; (R), root; (W),
stem wood; (B), stem bark; and (L), leaf. Extracts obtained using the same solvent are marked with the same color or color–texture.
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3.2. Ellagic Acid Derivatives and Ellagitannins in A. Leiocarpa and Their Suggested Impact on Its
Antimycobacterial Effects
In our screenings, the lowest MIC value (625 µg/mL) against M. smegmatis was obtained with
an ethyl acetate extract of the roots of A. leiocarpa. The good antimycobacterial effects of this extract could
have been due to ellagic acid derivatives and ellagitannins in this extract. In addition, we observed
that the antimycobacterial effects of a methanol extract of the root (MIC 2500 µg/mL) was improved
when it was fractionated using preparative reversed phase RP18-TLC and methanol:water:acetic acid
(50:50:1) as eluent. When compared to the crude extract, fractions 3 and 4, enriched with ellagic
acid derivatives, gave lower MIC values of 1500 and 1000 µg/mL, respectively (Table 2). Di-methyl
ellagic acid xyloside (Figure 3D) is especially suggested to strongly contribute to the antimycobacterial
effects of both fractions (Figure 5 and Table 3), since di-methyl ellagic acid xyloside inhibited the
growth of Mycobacterium intracellulare and showed an outstanding MIC value of 4.88 µg/mL against
M. smegmatis and M. tuberculosis MTCS2 [39]. The differences in MIC values, when compared to our
study (4.88 µg/mL versus 1000–1500 µg/mL in our study) could have been due to the fact that our thin
layer fractions contained a small total concentration of di-methyl ellagic acid xyloside (4.9% and 9%
peak area in HPLC-DAD chromatograms, in fraction 3 and 4, respectively) and, in addition, contained
a mixture of unknown ellagic acid derivatives. Moreover, Kuete et al. [39] used a different strain of
M. smegmatis. Besides, di-methyl ellagic acid xyloside has also been identified from the stem bark of
another species of Anogeissus, A. latifolia [40].
The xylose sugar part of di-methyl ellagic acid xyloside is thought to be important for its
antimycobacterial activity [41], and accordingly, the aglycone di-methyl ellagic acid was found to
be less active. In agreement with this, our screening result of ellagic acid against M. smegmatis
(MIC 500 µg/mL) showed that pure ellagic acid is not very active, and it needs to have a sugar molecule
or other side groups attached to increase its activity. Thus, ellagic acid derivatives, and especially
ellagic acid glycosides from Anogeissus leiocarpa (Figure 3) and related species, might have a significant
value as scaffolds for new anti-TB drugs.
Another ellagic acid derivative isolated from A. leiocarpa, 3,3,4′-tri-0-methyl-flavellagic acid, was
found to inhibit the growth of S. aureus, E. coli, and P. aeruginosa [42] but was not tested for its growth
inhibition against mycobacterial strains. Thus, Anogeissus spp. are good sources for antibacterial ellagic
acid derivatives with antibacterial properties.
Though some ellagic acid derivatives have been found to give strong antimycobacterial effects,
not much is known about their mechanisms of action on Mycobacterium spp. It has been suggested that
ellagic acid derivatives interfere with mycobacterial cell wall synthesis [43]. In accordance with this
suggestion, a study revealed that pteleoellagic acid had a high in silico docking score to MabA, a protein
involved in the fatty acid elongation complex II (FAS II) system in M. tuberculosis [44]. Additionally,
di-methyl ellagic acid xyloside inhibits arabinogalactan synthesis in the mycobacterial cell wall [43,44].
A. leiocarpa roots and stem bark are rich source of ellagitannins (ET). In this investigation,
we found that an ethyl acetate extract of A. leiocarpas roots gave the lowest MIC of 625 µg/mL against
M. smegmatis (Table 2). The good antimycobacterial effects of this extract could partly be attributed
to its ellagitannins. Moreover, we found that an ethyl acetate extract of the stem bark, enriched with
ellagitannins, gave fairly good antimycobacterial activity. In our previous investigation, we tentatively
characterized ten unknown ellagitannins in this stem bark ethyl acetate extract of A. leiocarpa based
on HPLC-UV-DAD data (UVλ maxima and retention times) [18]. Moreover, previously reported
ellagitannins in the stem bark and leaves of A. leiocarpa include a corilagin sanguiin H-4, punicalagin,
castalagin (1-epi-vescalagin), casuarinin, chebulagic acid, and punicacortein (Figure 7) [26,31].
These mentioned ellagitannins may play a significant role for the in vitro antimycobacterial effect of
the stem bark ethyl acetate extract of A. leiocarpa that we present in this paper. In this respect, we found
that corilagin expressed a mild growth inhibitory effect against M. smegmatis with an MIC value of
1000 µg/mL (Table 2). Some other ellagitannins are also known to possess in vitro growth inhibitory
effects against mycobacterial strains. For example, Asres et al., 2001 [45] found that punicalagin isolated
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from the stem bark of Combretum molle completely inhibited the growth of M. tuberculosis ATCC 27294
at a concentration of 1000 µg/mL, and Diop et al., 2019 [46] found that fractions enriched with the
ellagitannin isomers punicalagin α and β effectively inhibited the growth of Mycobacterium marinum,
whereas a fraction enriched with punicacortein D showed a weaker effect.
However, ETs are mostly too large to be absorbed as such in vivo, and in the human body, they are
mainly present as their degradation products of urolithins [47]. Thus, the role of ETs in anti-TB traditional
remedies might mostly be due to their metabolically available products, the urolithins [46,48]. Since we
also found that the same ellagitannins were present in a water extract of the stem bark of A. leiocarpa
(HPLC-DAD result not published), this could justify the traditional use of water extracts (decoctions
and macerations) of A. leiocarpa for the treatment of tuberculosis and its symptoms, such as (bloody
and prolonged) cough, assuming that the urolithins and ellagic acid and its derivatives, resulting from
the degradation of the ETs would be antimycobacterially active or that some metabolically unchanged
smaller molecular ETs would be active constituents in the extract. Accordingly, in their investigation
on antimycobacterial compounds of Combretum aculeatum, Diop et al., 2019 [46] suggested that the
effects of the traditional decoction of this plant could mostly be due to ellagic acid and urolithins.
In vitro investigations on the mechanism of action of ETs on bacteria have indicated that
the presence of galloyl groups and the presence and number of dehydro-hexahydroxydiphenoyl
ester (D-HHDP) and hexahydroxydiphenoyl ester groups (HHDP) in ellagitannins influence their
antimicrobial effects [9,49,50].
3.3. Flavonoids in A. Leiocarpa and Their Suggested Impact on Its Antimycobacterial Effects
Our results indicated that a methanol Soxhlet extract of the root of A. leiocarpa
have antimycobacterial effects. Flavonoids could have partly been behind these effects,
since in our previous investigation, we found that this extract is rich in flavonoids, such as
aromadendrin (syn. dihydrokaempferol), ampelopsin (syn. dihydromyricetin), methyl-taxifolin
(syn. dihydroisorhamnetin), and taxifolin (syn. dihydroquercetin) [18]. Moreover, we have now
found some additional flavonoids in this root extract, as shown in Figure 5A, at HPLC-UV-DAD Rt
4.74, 8.64, 14.37, and 14.38 min. The molecular masses for these flavonoids remain to be elucidated.
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Figure 7. Chemical structure of ellagitannins identified from Anogeissus spp. and A. leiocarpa: (A) flavano-ellagitannin anogeissinin A, (B) anogeissinin B, (C) cornusiin B,
(D) anogeissinin, (E) casuarinin, (F) castalagin (R1 = H; R2 = OH) and vescalagin (R1 = OH; R2 = H), (G) corilagin, and (H) isomer of corilagin sanguiin H4. DHHDP:
dehydro-hexahydroxydiphenoyl; HHDP: hexahydroxydiphenoyl. Source for molecular structures: CAS, 2020.
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Previous research has demonstrated that methanol and water extracts of the stem bark and leaf of
Anogeissus leiocarpa are rich in flavonoids such as luteolin, apigenin, quercitrin, isorhamnetin, isoquercetin,
quercetin-3-O-glucoside, luteolin-7-O-glucoside, kaempferol, rutin, quercetin-O-galloylhexoside,
myricetin-O-hexoside, apigenin-6-C-glucoside, reinutrin, avicularin, myricetin, guaijaverin, eriodictyol,
narcissin, naringenin, pinocembrin, quercetin, catechin, and vitexin [26,32,42]. In addition the dimer,
procyanidin B-2 was found to be present in an ethyl acetate extract of the leaves [32].
Some flavonoids occurring in A. leiocarpa have been tested for their antimycobacterial effects.
For example, taxifolin was found to give outstanding growth inhibitory effects against M. tuberculosis
H37Rv with an MIC value of ≤ 12.5 µg/mL [51,52]. Thus, the taxifolin that we found in high
concentrations in a methanolic root extract of A. leiocarpa could be an important contributor to
the growth inhibitory effects of this extract against M. smegmatis. Additionally, isorhamnetin showed
potent growth inhibitory effects against multi-drug and extensively drug-resistant clinical strains of
M. tuberculosis H37 Rv [53]. Moreover, quercetin-3-O-glucoside gave an MIC of 150 µg/mL against
M. tuberculosis H37 Rv [54]. Most of the flavonoids that have been investigated for their antimycobacterial
effects have been found to possess moderate to weak growth inhibitory effects. For example, quercetin
showed MIC values of 200 µg/mL against M. tuberculosis H37 Rv [55], and luteolin gave an MIC value of
699 µM against M. tuberculosis [56]. Thus, our results on the weak growth inhibitory effects of apigenin
and quercetin against M. smegmatis (both flavonoids gave MIC values of 250 µg/mL in our test system)
are in line with these previous findings.
Many authors’ results have suggested that the (most of the) flavonoids in plant extracts (including
extracts of A. leiocarpa) act in concert with other compounds present in the extracts, rather than
functioning as the principal antimycobacterial compounds alone. Indeed, it has been found that
fractions containing combinations of flavonoids, such as a fraction enriched in quercetin and guercitrin
isolated from a Brazilian medicinal plant Scutia buxifolia (Rhamnaceae), gave promising growth
inhibitory effects against M. smegmatis (MIC 78 µg/mL) [57]. Moreover, some flavonoids have been
found to act synergistically with conventional antimycobacterial drugs. For example, a trihydroxylated
methoxychalcone isolated from Galenia africana (Aizoaceae) was found to have synergistic effects in
combinations with isoniazid against M. tuberculosis [58]. In addition, some flavonoids have been
found to possess powerful antimycobacterial effects when tested alone, such as isobachalcone
(MIC 2.2 µg/mL against M tuberculosis) isolated from the West-African plant Dorstenia barteri
(Moraceae) [59]. Thus, in depth efforts should be made to investigate the flavonoid components
in Anogeissus spp. and to isolate these flavonoids in order to investigate their antimycobacterial
effects alone and in combinations with other flavonoids and with conventional anti-TB drugs, such as
rifampicin and isoniazid.
Some structure–activity relations and mechanisms of action have been studied regarding the
antimycobacterial effects of flavonoids. It has been found that the antimycobacterial potential of
flavonoids is mainly dependent on the presence of a heterocyclic ring, the presence and position of
functional groups (-OH, -OMe) and a carbon composition of C6-C3-C6 in their molecular structure [60].
Additionally, it has been found that the flavonoid structure is suitable for the development of
M. tuberculosis proteasome inhibitors [61,62]. DNA-gyrase in M. tuberculosis is an important drug
target, and taxifolin and quercetin are able to bind to this protein [52,63]. Moreover, flavonoids have
lipid peroxidation activity and antioxidant activity, which could also affect their antimycobacterial
potential [64]. Additionally, some flavonoids, such as butein and isoliquiritigenin have been found to
inhibit fatty acid and mycolic acid synthesis and thus to affect the formation of the mycobacterial cell
membrane and cell wall [3].
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4. Materials and Methods
4.1. Plant Material
The plant material of Anogeissus leiocarpa was collected from a natural woodland forest in the
Blue Nile region in southeastern Sudan (Figure 1). The plants were identified and authenticated at
the Faculty of Forestry, University of Khartoum, Sudan, and voucher specimen and voucher numbers
were deposited at the University of Khartoum, Sudan. The stem, leaves, fruits, and roots of the plant
specimens were air-dried in the shade. Stems and roots were manually debarked to separate the stem
bark from the wood and the root bark from the root. The dried plant parts were manually chipped to
small pieces and ground using a grinder machine.
4.2. Extraction
4.2.1. Cold and Hot Methanol Extraction
For the cold methanol extraction, 20 g of the plant material was added to 400 mL of methanol and
stirred overnight in a magnetic stirrer (RCT basic digital). The resulting extracts were centrifuged at
2500 rpm for 10 min (Eppendorf AG centrifuge 5810 R, Germany), whereafter the supernatants were
freeze-dried in a lyophilizer (HETO LyoPro 3000, Denmark) for three days.
For the hot methanol extraction using the Soxhlet technique, 800 mL of methanol was added
to 20–100 g of powder from various plant parts. Extraction was performed for 5 hours. A rotary
evaporator (Heidolph VV2000) was used to evaporate the solvent of the extracts, after which the
extracts were freeze-dried for 1–2 days.
The extracts obtained from these methods were dissolved in methanol (50 mg/mL) for
antimycobacterial screening. Additionally, the methanolic Soxhlet extracts at 5 mg/mL (in MeOH: H2O,
1:1) were subjected to further UHPLC/QTOF-MS phytochemical analysis.
4.2.2. Macerations and Hot Water Decoctions
Cold and hot water extracts were prepared in accordance with African traditional medicinal
knowledge. For the macerations, 500 mL of distilled water was added to 20 g of the plant powder and
extracted for 24 h using a magnetic stirrer (RCT basic digital). For the decoctions, 500 mL of water
were added to the plant powder and left to boil for 5 min.
Extracts obtained from both methods were transferred into Eppendorf centrifuge tubes
(volume 50 mL, Germany) and centrifuged at 3000 rpm (Eppendorf AG centrifuge 5810 R, Germany)
for 15 min. The resulting supernatants were collected and filtered using a vacuum pump filtration
technique and Whatman filter paper ( 150 mm, Germany). The filtered extracts were placed in
−20 ◦C for 24 h, whereafter they were lyophilized to dryness for 1–3 days using a (HETO LyoPro 3000,
Denmark) lyophilizer.
4.2.3. Sequential Extraction and Solvent Partition
In brief, sequential extraction was performed according to the method described by
Salih et al. 2017a and 2017b [18,65]. A total of 100 g of the plant materials of A. leiocarpa were
subjected to a sequential extraction method using solvents with increasing polarities. First, the plant
material was extracted with hexane (1000 mL), followed by dichloromethane or chloroform (1200 mL)
and acetone (900 mL) in the case of the root and root bark. Following this sequential extraction,
liquid–liquid fractionation was used. In this method, ethyl acetate was added to extracts that contained
80% methanol, and separation was performed in a separation funnel (a Nalgene®FEP). All extracts
were dried in the rotary evaporator, whereafter they were freeze-dried in a lyophilizer. The obtained
extracts were subjected to antimycobacterial testing.
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The percentage extraction yields for the extracts were calculated as the ratio of the extract
dry weight to the dry weight of the plant material used for the extraction according to the below
formula [66]:
Percentage extraction yield (%) = (
weight of the dry extract
weight of dry plant material before extraction
) × 100
4.3. Phytochemical Analysis
4.3.1. Thin Layer Chromatography and Antioxidant Analysis Using The DPPH-Reagent
A root extract of A. leiocarpa, extracted using hot methanol Soxhlet extraction, was subjected to
preparative and analytic reversed phase TLC and antioxidant analysis to isolate fractions enriched with
ellagic acid derivatives and to detect the antioxidant compounds in these fractions. Reversed phase
silica gel (RP18 F 254 s, Merck, Germany) plated glass plates (20 × 20 cm) were used for the separations,
and aluminum backed plates with the same solid phase were used for analytical TLC. A volume of
10 µL of the standard compounds, ellagic acid, corilagin, and gallic acid (Sigma-Aldrich, 1 mg/mL) was
applied on the thin layer plates. Additionally, 20–30 µL of extracts in methanol (50 mg/mL) were applied
in 5–10 µL volumes at a time (using a glass Pasteur pipette, P 4518-5X, Accupipette TM Pipets/ DADE
and DURAN®, ring Caps, Germany) at the baseline of the thin layer plate and allowed to dry between
the applications. Compound and pure compound applications were repeated 2–3 times. The eluent
for the TLC separations consisted of methanol:water:orthophosphoric acid (50 mL:50 mL:1000 µL).
The plates were developed until the solvent front reached 12.7 cm (application baseline at 1.5 cm).
The dried plates were examined under a UV-detector (Camaq Reprostar 3 TLC Visualizer) to identify
the fluorescent and quenching bands at 366 and 254 nm, respectively. The retardation factor (Rf) of the
fractions was measured using the below formula as the relation of the distance moved by the fractions
to the distance moved by the eluent front:
Rf =
Distance moved by the fractions
Distance moved by the solvent
For the preparative thin-layer fractionation, the fractions were scraped from 15 plates, and
bands showing the same Rf value were combined into the same glass tube. Methanol (2–5 mL) was
added to the glass tubes with the fractions in order to extract the compound (-s) from the silica gel.
After this extraction step, the glass tubes were centrifuged at 5000 rpm for 10 minutes (Mini Spin®
plus, Eppendorf, Germany) and the supernatants were collected. In order to obtain the dry weights of
the obtained fractions, the methanol was evaporated using a heating centrifuge (Concentrator Plus,
Eppendorf), whereafter the separated fractions were weighed and dissolved in methanol:water (1:1)
for HPLC-DAD- and UHPLC/QTOF MS-analysis.
The DPPH (2,2-diphenyl-1-picrylhydrazyl, C18H12N5O6, Sigma-Aldrich) reagent (0.2% w/v in
methanol) was used for the qualitative evaluation of the oxidative reaction of the separated spots
on the thin layer plates in visual light. The antioxidant compounds turned their color from violet to
yellowish or colorless due to reactions and neutralization with the DPPH of the various functional
groups in the detected compounds. The separated spots were compared with the standard compounds
corilagin, ellagic acid, and gallic acid (Sigma-Aldrich).
4.3.2. HPLC-UV/DAD Method
Analysis was performed using the Agilent Chemstation HPLC-UV/DAD system (Waters Corp.,
Milford, USA) and employing the method described by Salih et al. 2017a [18] and Salih 2019 [9].
The HPLC was connected with a controller, a water pump (600 E), and a diode-array detector UV
(a 991 PDA). The separation was performed using an analytical Hypersil reversed phase C-18 column
(length: 10 mm; ID: 2 mm). The eluents of the mobile phase consisted of solvent A, an aqueous solution
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that consisted of 1.5% tetrahydrofuran and 0.2% of orthophosphoric acid, and solvent B, which was
100% methanol. Gradient elution was used as described by Salih et al., 2017a [18], and the flow rate and
injection volume were 2 mL/min and 10 µl (2 mg/mL in 50% MeOH), respectively. The wavelengths
were set at 220, 270, 280, 320, and 360 nm, and the UVλ absorption maxima spectra of the identified
compounds were recorded. The compounds were compared with a natural compounds library
available in the computer Agilent Chemstation library. Moreover, the compounds were compared
with data reported in literature [9,18,67,68].
4.3.3. UHPLC/Q-TOF MS Method
The methods described by Taulavuori et al. 2013 [69], Fyhrquist et al., 2014a [34],
and Salih et al. 2017a [18] and Salih 2019 [9] were used to characterize the compounds of interest
and to obtain the molecular ions in negative mode as [M-H]- values. The UHPLC/Q-TOF MS
apparatus was equipped with UHPLC-DAD for the compound separations (Model 1200 Agilent
Technologies)-JETSTREAM/QTOFMS (Model 6340 Agilent Technologies) and a reversed phase column
(2.1 × 60 mm, 1.7 µm C18 column, Agilent technologies). The mobile phase included solvent A, 1.5%
of tetrahydrofuran and 0.25% of acetic acid in ionized water, and solvent B was 100% methanol.
The UHPLC-runs were made using the following gradient: from 0 to 1.5 min, 0% B; from 1.5 to 3 min,
0–15% B; from 3 to 6 min, 10–30% B; from 6 to 12 min, 30–50% B; from 12 to 20 min, 50–100% B;
and from 20 to 22 min, 100–0% B. All molecular ions were acquired in the negative ion mode with the
mass range from 100 to 2000 m/z. The acquired ions were compared with the literature [67].
4.4. Antimycobacterial Activity Tests
4.4.1. Agar Diffusion Method
The methods described by Fyhrquist et al. 2014 b [70] and Salih et al. 2018 [71] were used.
Mycobacterium smegmatis ATCC 14468 was grown for five days at +37 ◦C on agar slants containing
a Löwenstein–Jensen agar medium (Becton–Dickinson and Company, USA). For the test, petri dishes
(Ø 14 cm, Bibby Sterilin, UK) that were filled with a base layer of 25 mL agar (Antibiotic medium
Number 2, Difco, Molesey, UK) and 25 mL Middlebrook 7H10 agar (Difco) supplemented with oleic
albumin dextrose catalase supplement (OADC, Difco) as a top layer were used. 200 µL of Mycobacterium
suspension in sodium chloride (0.9% w/v) containing approximately 1.0 × 108 CFU/mL was aseptically
applied to the petri dish. After this inoculation, filter paper disks (Ø 12.7 mm, Schleicher and Schuell)
loaded with 200 µL of the extracts (50 mg/mL) and the positive control, rifampicin (10 mg/mL,
Sigma-Aldrich) were aseptically and equidistantly placed on the petri dishes. Then, 200 µL of the
solvents that were used to dissolve the plant extracts, methanol and hexane, were used as negative
controls. Prior to incubation, all petri dishes containing extracts and positive and negative controls were
left in the cold room (+4 ◦C) for two hours. Incubation was at +37 ◦C for five days. Experiments were
performed in triplicates and the diameters of the IZD were measured in millimeters. The results were
expressed as the mean IZD of the triplicates ± standard error of means (SEM). Moreover, the activity
index (AI) of the various extracts was evaluated as the relation of the IZD of the extracts compared to
the IZD of rifampicin, as shown in the equation below [70].
AI (Activity Index) =
Inhibition zone of the plant extract
Inhibition zone of rifampicin
Agar diffusion was used for the measurement of approximate MIC values for some of the extracts
due to the excess turbidity resulting from precipitation of the compounds in these extracts (such as some
methanol and hexane extracts). Thus, the MIC values for these extracts could not be measured with the
microplate method. In brief, for these experiments, 200 µL of two-fold dilutions of the extracts were
prepared (5 mg/mL–39 µg/mL dilutions) and pipetted on filter papers to determine the MIC value for
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these extracts. The lowest concentration that showed a small but still visible inhibition zone (≤1 mm)
was considered as the minimum inhibitory concentration.
4.4.2. Turbidimetric Microplate Method
Using the methods described in Fyhrquist et al. 2014 b [70] and Salih et al. 2018 [71],
extracts, pure compounds, positive and negative controls, and fractions obtained from the thin
layer chromatography were subjected to a turbidimetric microplate test to obtain the minimum
inhibitory concentration. Two-fold dilutions of the plant extracts were made in methanol from
5 to 39 µg/mL. The preparative TLC fractions (Fr 3, 4, 6, and 8) from a methanolic root extract of
A. leiocarpa were diluted in methanol to achieve concentrations of 1500, 1000, 2000, and 3000 µg/mL,
respectively, and two-fold dilutions were made from these stock solutions until 3.91 µg/mL was
reached. Rifampicin was diluted from 1000 to 1.953 µg/mL). The standard compounds, gallic acid
(G-7384, Sigma-Aldrich, Dermstadt, Germany), ellagic acid (Sigma-Aldrich), corilagin (Sigma-Aldrich),
quercetin (Merk Art. 7546, Darmstadt, Germany), and apigenin (Etrasynthese 69730 Genay, France)
were used as reference compounds that are known to occur in A. leiocarpa. These reference compounds
were prepared as two-fold dilutions from 1000 to 0.030 µg/mL.
Before the microplate test, a few colonies of Mycobacterium smegmatis ATCC 14468 were transferred
to 15 mL of the Dubos broth (Difco) and incubated for three days at +37 ◦C and 200 rpm. For the test,
2 mL of the suspension were pipetted into a glass tube; 1 mL was then pipetted into a disposable
UV Cuvette (BrandTech®, Essex, NJ, USA) to measure the turbidity at 625 nm using a UV–visible
spectrophotometer (Pharmacia LKB-Biochrom 4060). The remaining suspension in the glass tube was
then diluted to reach an absorbance of 0.1 (containing approximately 1 × 108 CFU/ mL). This suspension
was diluted further according to the guidelines of the Clinical and Laboratory Standards Institute
2013 [72], who recommend an inoculum of 2.5 × 105 CFU/mL for Mycobacterium smegmatis MIC
testing. A volume of 100 µl of suspension containing 5 × 105 CFU/mL was added to the 96-well
microplate wells (Nunc, Nunclon, Roskilde, Denmark) containing 100 µL of extracts, TLC fractions,
pure compounds, or rifampicin, thus resulting in a final inoculum of 2.5 × 105 CFU/mL. A total of
100 µL of the growth control (bacterial suspension containing 5 × 105 CFU/mL) and 100 µL of broth
were added to the growth control wells to reach the same CFU/mL as in the test wells (a final inoculum
of 2.5 × 105 CFU/mL). Moreover, solvent controls (methanol and hexane) were added to the wells
in the same maximum percentages as in the wells containing the highest concentrations of extracts
(that meant a maximum volume percentage of 5% for the solvents). The solvents (at max. 5% volume
of the suspension) were found to not be toxic to M. smegmatis. The microplates were incubated at
+37 ◦C for four days, whereafter the turbidity of the wells was measured at 620 nm using a Victor 1420
(Wallac, Turku, Finland) spectrophotometer.
All assays were done in triplicate, and as shown in the equation below, the results are expressed as
the mean percentage of growth inhibition of triplicates compared to the growth of the growth control
(= 100% growth). Sample controls (SC, containing only plant extract and broth, without bacterium)
were used to subtract the turbidity resulting from the plant extracts (the turbidity of test well with
plant extract and bacterium minus turbidity of sample control containing the same plant extract but no
bacteria). The smallest concentration that inhibited ≥90% of the mycobacterial growth was considered
as the MIC value [71].
Formula (1 and 2) used for the calculation of growth inhibition:
% bacterial growth =
[
( xGT A620 − xSC A620)
xGC A620
× 100
]
(1)
% inhibition of growth = 100 (% growth of the growth control) −
[
( xGT A620 − xSC A620)
xGC A620 × 100
]
(2)
where GT A620 is the turbidity of the test well at 620 nm (containing plant samples, pure compounds
or antibiotics and microbial cells), SC A620 is the sample control (consisting of the plant samples,
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the compounds or antibiotics alone, without microbial cells), and GC A620 is the turbidity of the growth
control at 620 nm (containing only bacterial cells). x is the average of the triplicates.
In addition, the total activity of a plant extract was calculated as the mass extracted from the plant
material (in mg/1000 mg starting material) divided by the MIC (in mg/mL) value of this extract.
5. Conclusions
The results from this investigation indicated that extracts of the African medicinal plant
Anogeissus leiocarpa contains compounds that might have use for the treatment of tuberculosis.
Our results could justify the traditional oral application of utilizing water extracts and decoctions of
A. leiocarpa roots, leaves, and stem bark to treat cough related to TB. Moreover, our results indicate
that ethanol extracts could be preferred for traditional use, since alcohol extracts more compounds
than water.
To the best of our knowledge, this is the first time extracts and fractions of A. leiocarpa have
been tested for their antimycobacterial effects against M. smegmatis. Our RP18-TLC fractionation of
A. leiocarpa roots resulted in the separation of some ellagic acid enriched fractions that were more active
than the crude methanol extract. Of the active compounds in these fractions, di-methyl ellagic acid
and di-methyl ellagic acid xyloside were enriched in some of the fractions, and these compounds have
been found to possess promising antimycobacterial effects. Thus, A. leiocarpa could be a good source
for these antimycobacterial ellagic acid derivatives.
Ellagic acid-based glycosides are difficult to synthesize due to the O-glycosylation step, and thus
the possibility to use plants (and their renewable organs such as leaves) as sources for EA glycosides
should be investigated.
Our results indicate that in addition to its ellagic acid derivatives, A. leiocarpa contains a high
variety of compounds with potential antimycobacterial activity such as flavonoids (especially taxifolin)
and stilbenes (pinosylvin and 4′-methylpinosylvin). Moreover, a number of ellagitannins have been
characterized in A. leiocarpa that could have good antimycobacterial effects in vivo via their metabolically
available urolithins.
Further in-depth studies should be performed on fractions and compounds isolated from
A. leiocarpa, to investigate their individual effects on various strains on M. tuberculosis, as well to study
the antimycobacterial potential of extracts and isolated fractions/compounds in combinations with
conventional anti-TB drugs, such as rifampicin and isoniazid.
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